Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 11;151(6):396-399.
doi: 10.1161/CIRCULATIONAHA.124.072973. Epub 2025 Feb 10.

Antagonizing HFpEF by Targeting Fibrosis

Glynnis Garry Bann  1
Affiliations
Editorial

Antagonizing HFpEF by Targeting Fibrosis

Glynnis Garry Bann. Circulation. .
No abstract available

Keywords: Editorials; heart failure, diastolic.

PubMed Disclaimer

Conflict of interest statement

G.G. Bann is an inventor on US patent application (18/706,525) based on International Patent Application (PCT/US2022/078854) entitled “Reprogramming of Adult Cardiac Fibroblasts Into Cardiomyocytes using PHF7” in the name of the Board of Regents of the University of Texas System.

Figures

Figure.
Figure.. Targeting pathological fibroblast transdifferentiation in HFpEF with the reprogramming factor Gata4.
Overexpression of Gata4 in cardiac fibroblasts reverses the HFpEF phenotype through repression of fibroblast activation and profibrotic signaling.
See this image and copyright information in PMC

Comment on

References

    1. Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, Fonarow GC, Heidenreich P, Ho JE, Hsich E, et al. ; Writing Committee Members. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023;29:1412–1451. doi: 10.1016/j.cardfail.2023.07.006 - DOI - PMC - PubMed
    1. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175:996–1004. doi: 10.1001/jamainternmed.2015.0924 - DOI - PMC - PubMed
    1. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, et al. ; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392. doi: 10.1056/NEJMoa1313731 - DOI - PubMed
    1. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, et al. ; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461. doi: 10.1056/NEJMoa2107038 - DOI - PubMed
    1. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, et al. ; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–1084. doi: 10.1056/NEJMoa2306963 - DOI - PubMed

LinkOut - more resources